US FDA Panel Will Reckon With Need For Diabetes Drug CV Risk Assessments

Cardiovascular and non-CV safety findings from completed outcomes trials to date for eight drugs, as well as the relative paucity of preapproval CV data available for anti-diabetic agents prior to a December 2008 guidance that mandated dedicated risk assessments, may inform advisory committee's view on continuing need for large safety trials.

Diabetes-Concept_56048224_1200x675

Whether sponsors of new type 2 diabetes drugs must continue to exclude an unacceptable increase in cardiovascular (CV) risk is the lone voting question being put to the US FDA’s Endocrinologic and Metabolic Drugs Advisory Committee at an Oct. 24-25 meeting.

However, in deciding that question, FDA wants the panel be mindful of the CV and non-CV safety findings that have...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers